Skip to content
The Policy VaultThe Policy Vault

zolmitriptan nasal sprayCareFirst (Caremark)

Migraine headache

Initial criteria

  • Patient does NOT have confirmed or suspected cardiovascular OR cerebrovascular disease OR uncontrolled hypertension
  • Medication overuse headache has been considered AND ruled out
  • Patient meets ONE of the following: currently using migraine prophylactic therapy OR unable to take migraine prophylactic therapies due to inadequate treatment response, intolerance or contraindication [Examples of prophylactic therapy include divalproex sodium, topiramate, valproate sodium, metoprolol, propranolol, timolol, atenolol, nadolol, candesartan, amitriptyline, venlafaxine, erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant]
  • Patient meets ONE of the following: the requested drug is NOT being used concurrently with another triptan 5-HT1 agonist OR the requested drug is being used concurrently with another triptan 5-HT1 agonist AND patient requires more than one triptan 5-HT1 agonist due to clinical need for differing routes of administration

Approval duration

12 months